Roivant Sciences Equity 2025

Roivant Sciences Aktienanalyse

What does Roivant Sciences do?

Roivant Sciences Ltd is a biopharmaceutical company based in Basel, Switzerland. It was founded in 2014 by Vivek Ramaswamy, a former hedge fund manager. The company's idea was to develop "orphan molecules," which are drug compounds that have not been further developed by large pharmaceutical companies for various reasons. Roivant Sciences' business model is based on identifying therapy areas with high unmet medical needs. It then collaborates with academic institutions and other partners to search for orphan molecules that could be potentially interesting for these therapy areas. The molecules are further developed in the company's internal research and development laboratories. Roivant Sciences has established seven different subsidiary companies through its innovative approach to drug development and acquisition of other companies. Some of the most well-known subsidiaries include Axovant Sciences, Dermavant Sciences, Enzyvant Therapeutics, and Myovant Sciences. Each subsidiary of Roivant Sciences focuses on specific therapy areas. For example, Axovant Sciences focuses on developing therapies for neurological diseases such as Parkinson's and Alzheimer's, while Dermavant Sciences focuses on dermatology and Enzyvant Therapeutics concentrates on rare genetic diseases. Roivant Sciences has also raised a considerable amount of capital to finance its various companies. In 2017, the company raised $1.1 billion, expanding its presence in the global healthcare market. Products developed by Roivant Sciences' subsidiaries include Axovant's Nelotanserin, a potential medication for hallucinations and nightmares in Parkinson's patients, as well as Myovant's Leuprolide, a medication for treating prostate cancer. The company also has a partnership with Dartmouth College to advance research and development in neuroscience. The partnership aims to identify "specific molecular targets" for developing treatments for neurodegenerative diseases. In summary, Roivant Sciences Ltd is an innovative biopharmaceutical company that develops orphan molecules and specializes in various therapy areas. Its subsidiaries develop products for a range of diseases, from Alzheimer's to prostate cancer and rare genetic disorders. The company has raised a significant amount of capital to finance its operations and collaborates with academic institutions to advance its research and development. Roivant Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Roivant Sciences's Equity

Roivant Sciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Roivant Sciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Roivant Sciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Roivant Sciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Roivant Sciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Roivant Sciences stock

What is the equity of Roivant Sciences this year?

Roivant Sciences has equity of 5.97 B USD this year.

What was the equity of Roivant Sciences compared to the previous year?

The equity of Roivant Sciences has increased/decreased by 415.51% increased compared to the previous year.

What impact does a high equity have on investors of Roivant Sciences?

A high equity is advantageous for investors of Roivant Sciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Roivant Sciences?

A low equity can be a risk for investors of Roivant Sciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Roivant Sciences affect the company?

An increase in equity of Roivant Sciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Roivant Sciences affect the company?

A reduction in equity of Roivant Sciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Roivant Sciences?

Some factors that can affect the equity of Roivant Sciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Roivant Sciences so important for investors?

The equity of Roivant Sciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Roivant Sciences take to change the equity?

To change equity, Roivant Sciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Roivant Sciences pay?

Over the past 12 months, Roivant Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Roivant Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Roivant Sciences?

The current dividend yield of Roivant Sciences is .

When does Roivant Sciences pay dividends?

Roivant Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Roivant Sciences?

Roivant Sciences paid dividends every year for the past 0 years.

What is the dividend of Roivant Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Roivant Sciences located?

Roivant Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Roivant Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Roivant Sciences from 1/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2025.

When did Roivant Sciences pay the last dividend?

The last dividend was paid out on 1/2/2025.

What was the dividend of Roivant Sciences in the year 2024?

In the year 2024, Roivant Sciences distributed 0 USD as dividends.

In which currency does Roivant Sciences pay out the dividend?

The dividends of Roivant Sciences are distributed in USD.